<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04850014</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL20_1244</org_study_id>
    <nct_id>NCT04850014</nct_id>
  </id_info>
  <brief_title>PBPK Modelling Applied to Acetaminophen Poisoned Obese Children</brief_title>
  <acronym>IntoxPara</acronym>
  <official_title>Physiologically-based Pharmacokinetic Modelling Applied to Acetaminophen- Poisoned Obese Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Childhood obesity is increasing globally. Changes in body composition and physiology in&#xD;
      obesity setting modify pharmacokinetic parameters and might increase the risk in case of&#xD;
      poisoning. Acetaminophen is a drug often implied in poisoning in children population,&#xD;
      especially in adolescent attempting suicide. In practice, clinicians use weight to assess&#xD;
      intoxication severity, but depending on the weight chosen (actual weight, lean body weight,&#xD;
      ideal weight,..) the severity assessment can change as well as medical care needed. In this&#xD;
      context we hypothesize that a PBPK modelling would be helpful to predict toxic dosing in&#xD;
      obese population and especially in obese adolescent or children. The primary objective of&#xD;
      this study is to collect data related to acetaminophen-poisoned patient with at least one&#xD;
      acetaminophen concentration sampling and whose clinical outcome is known in order to refine&#xD;
      and validate such a PBPK model.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Acetaminophen concentration</measure>
    <time_frame>31 october 2021</time_frame>
    <description>With hour post-ingestion provided</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Poisoning</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Poisoned patients</arm_group_label>
    <description>All subjects with paracetamolemia in the context of paracetamol poisoning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Acetaminophen-poisoned patient being non-obese</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Anthropomorphism</intervention_name>
    <description>Height, weight, body surface area, body mass index, exact age (date of birth or age in days, months and years), falling which year of birth gender</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Poisoned patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Relevant clinical datas</intervention_name>
    <description>Medical history Concomitant medication Paracetamol intake : dosage, delay, context, route of intake Alcohol intake Smoking status (including active and passive exposition or no exposition) Curative treatment / Antidote / purifying treatment received and time of introduction Clinical signs, Acetaminophen concentration in plasma with associated accurate time of sampling (date, hour and time following acetaminophen intake Liver and kindney function assessment by measure measuring plasma concentration of: AST, ALT, Factor V, Prothrombin, APTT, INR, albuminemia, bilirubin, phosphorus, pH, creatitine. And GFR estimation.&#xD;
Imaging.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Poisoned patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        -  Poisoned acetaminophen subjects&#xD;
&#xD;
          -  At least one acetaminophen blood sample result available in data base&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All subjects &gt;/= 10 year old&#xD;
&#xD;
          -  Availability of at least one positive acetaminophen concentration with its associated&#xD;
             sampling time&#xD;
&#xD;
          -  Known clinical outcome&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt; 10 year old&#xD;
&#xD;
          -  lack of data-&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kim An NGUYEN, MD</last_name>
    <phone>4 72 31 94 11</phone>
    <phone_ext>+33</phone_ext>
    <email>kim-an.nguyen@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>SÃ©bastien RIVAS</last_name>
    <phone>6 43 09 51 20</phone>
    <phone_ext>+33</phone_ext>
    <email>sebastien.rivas.1@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim An NGUYEN, MD</last_name>
      <phone>4 72 31 94 11</phone>
      <phone_ext>+33</phone_ext>
      <email>kim-an.nguyen@chu-lyon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 14, 2021</study_first_submitted>
  <study_first_submitted_qc>April 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2021</study_first_posted>
  <last_update_submitted>April 14, 2021</last_update_submitted>
  <last_update_submitted_qc>April 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PBPK</keyword>
  <keyword>Modelling</keyword>
  <keyword>Acetaminophen</keyword>
  <keyword>Paracetamol</keyword>
  <keyword>Pediatrics</keyword>
  <keyword>Obesity</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Toxicokinetics</keyword>
  <keyword>Poisoning</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Poisoning</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

